{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [
    [
      "Cancer",
      "IGF2",
      "Immunosuppressive potential",
      "Invasiveness",
      "Metastasis",
      "Trophoblast"
    ]
  ],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "29523298",
  "DateCompleted": {
    "Year": "2018",
    "Month": "10",
    "Day": "15"
  },
  "DateRevised": {
    "Year": "2018",
    "Month": "10",
    "Day": "15"
  },
  "Article": {
    "ArticleDate": [
      {
        "Year": "2018",
        "Month": "02",
        "Day": "21"
      }
    ],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "10.1016/j.mehy.2018.02.019",
      "S0306-9877(17)30902-7"
    ],
    "Journal": {
      "ISSN": "1532-2777",
      "JournalIssue": {
        "Volume": "113",
        "PubDate": {
          "Year": "2018",
          "Month": "Apr"
        }
      },
      "Title": "Medical hypotheses",
      "ISOAbbreviation": "Med Hypotheses"
    },
    "ArticleTitle": "The role of trophoblastic epigenetic reprogrammation in benign tumor cells on malignant progression: A molecular hypothesis.",
    "Pagination": {
      "StartPage": "68",
      "EndPage": "71",
      "MedlinePgn": "68-71"
    },
    "Abstract": {
      "AbstractText": [
        "Cancer tissues and placental ones share many properties such as invasiveness, metastasis and local immunosuppressive effects. The goal of the present article is to hypothesize a theory about cancer origin that links placental and cancerous tissues at molecular level. This hypothesis explain that cancer origin could be due to low hypoxic conditions in the peripheral zones of benign tumors which might up-regulate the expression of IGF2, and, consequently, trophoblastic genes. In fact, many phenotypic characteristics and molecular markers are shared between these two cell types (cancerous and trophoblastics ones), providing evidences to support this hypothesis. As a consequence, it could be interesting to demonstrate whether cancer start with a cellular reprogrammation towards a trophoblastic fate in order to design new antitumoral strategies focused on this fact."
      ],
      "CopyrightInformation": "Copyright \u00a9 2018 Elsevier Ltd. All rights reserved."
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Medical Oncology Service, Virgen de las Nieves Hospital (Granada), Av. Fuerzas Armadas, sn, 18014 Granada, Spain. Electronic address: kdoello@correo.ugr.es."
          }
        ],
        "LastName": "Doello",
        "ForeName": "Kevin",
        "Initials": "K"
      }
    ],
    "PublicationTypeList": [
      "Journal Article"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "United States",
    "MedlineTA": "Med Hypotheses",
    "NlmUniqueID": "7505668",
    "ISSNLinking": "0306-9877"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Antineoplastic Agents"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Biomarkers, Tumor"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "IGF2 protein, human"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Immunosuppressive Agents"
    },
    {
      "RegistryNumber": "67763-97-7",
      "NameOfSubstance": "Insulin-Like Growth Factor II"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [
        "pharmacology"
      ],
      "DescriptorName": "Antineoplastic Agents"
    },
    {
      "QualifierName": [
        "metabolism"
      ],
      "DescriptorName": "Biomarkers, Tumor"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Diagnosis, Differential"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Disease Progression"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Epigenesis, Genetic"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Female"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Immunosuppressive Agents"
    },
    {
      "QualifierName": [
        "metabolism"
      ],
      "DescriptorName": "Insulin-Like Growth Factor II"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Models, Theoretical"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Mutation"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Neoplasm Invasiveness"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Neoplasm Metastasis"
    },
    {
      "QualifierName": [
        "genetics",
        "pathology"
      ],
      "DescriptorName": "Neoplasms"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Phenotype"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Placenta"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Pregnancy"
    },
    {
      "QualifierName": [
        "metabolism"
      ],
      "DescriptorName": "Trophoblasts"
    }
  ]
}